$8.00
16.84% yesterday
Nasdaq, Sep 03, 10:17 pm CET
ISIN
SG9999014716
Symbol
WVE

Wave Life Sciences Ltd. Stock price

$8.00
-0.75 8.57% 1M
-2.05 20.40% 6M
-4.37 35.33% YTD
+2.45 44.14% 1Y
+5.15 180.70% 3Y
-4.40 35.48% 5Y
-8.00 50.00% 10Y
-8.00 50.00% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-1.62 16.84%
ISIN
SG9999014716
Symbol
WVE
Industry

Key metrics

Basic
Market capitalization
$1.5b
Enterprise Value
$1.3b
Net debt
positive
Cash
$208.5m
Shares outstanding
155.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
16.3 | 30.9
EV/Sales
14.0 | 26.7
EV/FCF
negative
P/B
10.4
Financial Health
Equity Ratio
61.7%
Return on Equity
-44.6%
ROCE
-87.0%
ROIC
641.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$94.0m | $49.4m
EBITDA
$-132.5m | $-192.7m
EBIT
$-143.5m | $-200.2m
Net Income
$-129.9m | $-179.4m
Free Cash Flow
$-200.1m
Growth (TTM | estimate)
Revenue
-15.0% | -54.4%
EBITDA
-67.0% | -89.4%
EBIT
-71.5% | -81.3%
Net Income
-76.1% | -84.9%
Free Cash Flow
-54.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-141.1% | -390.0%
EBIT
-152.8%
Net
-138.2% | -363.0%
Free Cash Flow
-213.0%
More
EPS
$-0.8
FCF per Share
$-1.3
Short interest
14.2%
Employees
288
Rev per Employee
$380.0k
Show more

Is Wave Life Sciences Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Wave Life Sciences Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Wave Life Sciences Ltd. forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a Wave Life Sciences Ltd. forecast:

Buy
89%
Hold
11%

Financial data from Wave Life Sciences Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
94 94
15% 15%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 68 68
24% 24%
72%
- Research and Development Expense 170 170
22% 22%
181%
-133 -133
67% 67%
-141%
- Depreciation and Amortization 11 11
154% 154%
12%
EBIT (Operating Income) EBIT -144 -144
71% 71%
-153%
Net Profit -130 -130
76% 76%
-138%

In millions USD.

Don't miss a Thing! We will send you all news about Wave Life Sciences Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Wave Life Sciences Ltd. Stock News

Neutral
Seeking Alpha
about 13 hours ago
Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Joon Lee - Truist Securities, ...
Neutral
GlobeNewsWire
about 20 hours ago
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)
Neutral
The Motley Fool
about one month ago
Wave (WVE) Q2 Revenue Drops 56%
More Wave Life Sciences Ltd. News

Company Profile

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Head office Singapore
CEO Paul Bolno
Employees 288
Founded 2012
Website www.wavelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today